Aligos Therapeutics (ALGS) Change in Acquisitions & Divestments (2019 - 2026)

Aligos Therapeutics (ALGS) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $35.0 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 75.0% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $142.5 million (up 103.57% YoY) and the FY2025 annual result came in at $127.5 million, up 41.67% from the prior year.
• Change in Acquisitions & Divestments slipped to $35.0 million in Q1 2026, from $37.5 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $70.0 million in Q3 2025 to a low of $11000.0 in Q3 2023.
• A 5-year average of $30.1 million and a median of $30.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments slumped 99.97% — and 2024, when it soared 272627.27%.
• Tracing ALGS's Change in Acquisitions & Divestments over 5 years: stood at $36.2 million in 2022, then tumbled by 99.97% to $11000.0 in 2023, then jumped by 181718.18% to $20.0 million in 2024, then surged by 87.5% to $37.5 million in 2025, then slipped by 6.67% to $35.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $35.0 million (Q1 2026), $37.5 million (Q4 2025), and $70.0 million (Q3 2025), per Business Quant data.